| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Retinopathy of Prematurity | 19 | 2025 | 40 | 3.390 |
Why?
|
| Strabismus | 13 | 2025 | 20 | 3.380 |
Why?
|
| Ophthalmologic Surgical Procedures | 8 | 2025 | 24 | 2.570 |
Why?
|
| Oculomotor Muscles | 11 | 2025 | 18 | 2.100 |
Why?
|
| Visual Acuity | 28 | 2025 | 120 | 2.030 |
Why?
|
| Vision Disorders | 17 | 2019 | 38 | 2.000 |
Why?
|
| Ophthalmology | 9 | 2026 | 37 | 1.990 |
Why?
|
| Optic Nerve Diseases | 8 | 2021 | 16 | 1.840 |
Why?
|
| Diplopia | 6 | 2022 | 10 | 1.510 |
Why?
|
| Optic Nerve | 9 | 2021 | 28 | 1.360 |
Why?
|
| Child | 36 | 2025 | 2355 | 1.340 |
Why?
|
| Hamartoma | 2 | 2021 | 13 | 1.280 |
Why?
|
| Humans | 107 | 2026 | 29214 | 1.230 |
Why?
|
| Amblyopia | 3 | 2021 | 6 | 1.160 |
Why?
|
| Postoperative Complications | 5 | 2025 | 643 | 1.080 |
Why?
|
| Myopia | 5 | 2015 | 20 | 1.040 |
Why?
|
| Retinal Diseases | 4 | 2019 | 47 | 1.020 |
Why?
|
| Pseudotumor Cerebri | 6 | 2016 | 14 | 1.000 |
Why?
|
| Muscarinic Antagonists | 3 | 2015 | 14 | 0.950 |
Why?
|
| Female | 67 | 2026 | 15826 | 0.930 |
Why?
|
| Child, Preschool | 26 | 2025 | 1215 | 0.900 |
Why?
|
| Male | 60 | 2026 | 14127 | 0.880 |
Why?
|
| Infant, Premature | 9 | 2025 | 149 | 0.880 |
Why?
|
| Infant | 24 | 2025 | 1067 | 0.870 |
Why?
|
| Visually Impaired Persons | 2 | 2019 | 5 | 0.860 |
Why?
|
| Retrospective Studies | 25 | 2026 | 2662 | 0.820 |
Why?
|
| Ophthalmoplegia | 5 | 2020 | 8 | 0.810 |
Why?
|
| Registries | 2 | 2025 | 399 | 0.800 |
Why?
|
| Infant, Newborn | 22 | 2025 | 932 | 0.780 |
Why?
|
| Magnetic Resonance Imaging | 22 | 2020 | 847 | 0.770 |
Why?
|
| Vision, Monocular | 2 | 2019 | 2 | 0.710 |
Why?
|
| Adolescent | 23 | 2025 | 3255 | 0.700 |
Why?
|
| Eye Abnormalities | 3 | 2011 | 11 | 0.700 |
Why?
|
| Certification | 2 | 2016 | 16 | 0.700 |
Why?
|
| Follow-Up Studies | 12 | 2025 | 1033 | 0.690 |
Why?
|
| Visual Fields | 12 | 2016 | 35 | 0.670 |
Why?
|
| Quality Improvement | 2 | 2019 | 130 | 0.660 |
Why?
|
| Miller Fisher Syndrome | 1 | 2020 | 1 | 0.660 |
Why?
|
| Conjunctivitis | 1 | 2020 | 4 | 0.640 |
Why?
|
| Mucositis | 1 | 2020 | 7 | 0.640 |
Why?
|
| Pneumonia, Mycoplasma | 1 | 2020 | 9 | 0.640 |
Why?
|
| Exanthema | 1 | 2020 | 14 | 0.640 |
Why?
|
| Oxygen | 2 | 2012 | 238 | 0.630 |
Why?
|
| Eyeglasses | 1 | 2019 | 6 | 0.600 |
Why?
|
| Epiretinal Membrane | 1 | 2019 | 1 | 0.600 |
Why?
|
| Abducens Nerve Diseases | 3 | 2017 | 6 | 0.590 |
Why?
|
| Infant, Extremely Low Birth Weight | 1 | 2019 | 8 | 0.590 |
Why?
|
| Visual Pathways | 6 | 2007 | 17 | 0.580 |
Why?
|
| Optic Neuritis | 5 | 2003 | 14 | 0.570 |
Why?
|
| Internship and Residency | 4 | 2026 | 263 | 0.550 |
Why?
|
| Trochlear Nerve Diseases | 2 | 2017 | 5 | 0.550 |
Why?
|
| Oculomotor Nerve Diseases | 5 | 2017 | 9 | 0.530 |
Why?
|
| Vision Screening | 3 | 2011 | 5 | 0.500 |
Why?
|
| Telemedicine | 4 | 2025 | 228 | 0.500 |
Why?
|
| Vision, Binocular | 5 | 2011 | 8 | 0.490 |
Why?
|
| Pirenzepine | 2 | 2008 | 8 | 0.490 |
Why?
|
| Specialty Boards | 1 | 2016 | 11 | 0.490 |
Why?
|
| Education, Medical, Continuing | 1 | 2016 | 35 | 0.480 |
Why?
|
| Neonatal Screening | 3 | 2025 | 16 | 0.480 |
Why?
|
| Sarcoma, Myeloid | 1 | 2016 | 7 | 0.480 |
Why?
|
| Blepharoptosis | 1 | 2016 | 7 | 0.480 |
Why?
|
| Orbital Neoplasms | 1 | 2016 | 11 | 0.470 |
Why?
|
| Brain Diseases | 5 | 2007 | 36 | 0.470 |
Why?
|
| Giant Cell Arteritis | 2 | 2012 | 5 | 0.470 |
Why?
|
| Atropine | 1 | 2015 | 47 | 0.460 |
Why?
|
| Blindness | 7 | 2005 | 34 | 0.460 |
Why?
|
| Incidence | 7 | 2025 | 581 | 0.450 |
Why?
|
| Depth Perception | 2 | 2013 | 3 | 0.440 |
Why?
|
| Adult | 25 | 2026 | 8131 | 0.440 |
Why?
|
| Diabetes Complications | 3 | 2012 | 66 | 0.440 |
Why?
|
| Optic Nerve Glioma | 2 | 2006 | 2 | 0.420 |
Why?
|
| Aviation | 1 | 2013 | 1 | 0.410 |
Why?
|
| Perceptual Disorders | 1 | 2013 | 4 | 0.410 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2011 | 7 | 0.400 |
Why?
|
| Clinical Competence | 3 | 2016 | 249 | 0.390 |
Why?
|
| Esotropia | 2 | 2004 | 6 | 0.390 |
Why?
|
| Nystagmus, Pathologic | 2 | 2007 | 4 | 0.390 |
Why?
|
| United States | 9 | 2026 | 2270 | 0.380 |
Why?
|
| Educational Measurement | 3 | 2026 | 142 | 0.370 |
Why?
|
| Aged | 19 | 2025 | 5648 | 0.370 |
Why?
|
| Fixation, Ocular | 1 | 2011 | 3 | 0.360 |
Why?
|
| Middle Aged | 22 | 2025 | 7496 | 0.350 |
Why?
|
| Arnold-Chiari Malformation | 2 | 2018 | 14 | 0.350 |
Why?
|
| Biopsy | 1 | 2012 | 213 | 0.350 |
Why?
|
| Penicillamine | 1 | 2011 | 9 | 0.350 |
Why?
|
| Disease Progression | 7 | 2019 | 484 | 0.350 |
Why?
|
| Aged, 80 and over | 10 | 2025 | 2070 | 0.350 |
Why?
|
| Chelating Agents | 1 | 2011 | 22 | 0.340 |
Why?
|
| Risk Factors | 8 | 2025 | 2144 | 0.330 |
Why?
|
| Intensive Care, Neonatal | 1 | 2010 | 17 | 0.320 |
Why?
|
| Oxygen Inhalation Therapy | 1 | 2010 | 17 | 0.320 |
Why?
|
| Diabetes Mellitus | 2 | 2012 | 216 | 0.320 |
Why?
|
| Decompression, Surgical | 3 | 2018 | 81 | 0.320 |
Why?
|
| Education, Medical, Graduate | 3 | 2026 | 119 | 0.320 |
Why?
|
| Gestational Age | 9 | 2019 | 147 | 0.300 |
Why?
|
| Optic Chiasm | 2 | 2001 | 3 | 0.300 |
Why?
|
| Treatment Outcome | 11 | 2020 | 2443 | 0.290 |
Why?
|
| Retina | 3 | 2020 | 446 | 0.290 |
Why?
|
| Bevacizumab | 2 | 2020 | 106 | 0.280 |
Why?
|
| Religion | 1 | 2008 | 25 | 0.270 |
Why?
|
| Preoperative Care | 1 | 2008 | 81 | 0.260 |
Why?
|
| Spasms, Infantile | 1 | 2007 | 4 | 0.260 |
Why?
|
| Attitude to Health | 1 | 2008 | 91 | 0.260 |
Why?
|
| Physicians | 1 | 2008 | 83 | 0.250 |
Why?
|
| Intensive Care Units, Neonatal | 2 | 2025 | 60 | 0.250 |
Why?
|
| Optic Nerve Neoplasms | 1 | 2006 | 1 | 0.250 |
Why?
|
| Evoked Potentials, Visual | 1 | 2006 | 5 | 0.250 |
Why?
|
| Fluorescein Angiography | 2 | 2019 | 18 | 0.240 |
Why?
|
| Orbital Diseases | 2 | 1997 | 11 | 0.240 |
Why?
|
| Oculomotor Nerve | 2 | 2004 | 3 | 0.240 |
Why?
|
| Diagnostic Imaging | 2 | 2016 | 70 | 0.240 |
Why?
|
| Tomography, Optical Coherence | 3 | 2019 | 103 | 0.240 |
Why?
|
| Licensure, Medical | 1 | 2026 | 10 | 0.240 |
Why?
|
| Myositis | 2 | 1997 | 68 | 0.240 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2019 | 177 | 0.240 |
Why?
|
| Personnel Selection | 1 | 2026 | 11 | 0.240 |
Why?
|
| Infant, Very Low Birth Weight | 8 | 2016 | 23 | 0.230 |
Why?
|
| Plagiocephaly, Nonsynostotic | 1 | 2005 | 2 | 0.230 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2005 | 14 | 0.230 |
Why?
|
| Corneal Opacity | 1 | 2005 | 4 | 0.230 |
Why?
|
| Mosaicism | 1 | 2005 | 13 | 0.230 |
Why?
|
| Trisomy | 1 | 2005 | 19 | 0.230 |
Why?
|
| History, 20th Century | 2 | 2016 | 85 | 0.220 |
Why?
|
| Diagnosis, Differential | 5 | 2016 | 382 | 0.220 |
Why?
|
| Facial Hemiatrophy | 1 | 2004 | 1 | 0.220 |
Why?
|
| Recurrence | 4 | 2014 | 328 | 0.210 |
Why?
|
| Neurology | 1 | 2004 | 11 | 0.210 |
Why?
|
| Visual Field Tests | 3 | 2011 | 16 | 0.210 |
Why?
|
| Pediatrics | 2 | 2016 | 117 | 0.210 |
Why?
|
| Cerebellar Diseases | 1 | 2004 | 4 | 0.210 |
Why?
|
| Multiple Sclerosis | 4 | 2003 | 92 | 0.210 |
Why?
|
| Meibomian Glands | 1 | 2004 | 2 | 0.210 |
Why?
|
| Telangiectasis | 1 | 2004 | 3 | 0.210 |
Why?
|
| Eyelid Diseases | 1 | 2004 | 7 | 0.210 |
Why?
|
| Rosacea | 1 | 2004 | 3 | 0.210 |
Why?
|
| Corneal Ulcer | 1 | 2004 | 12 | 0.210 |
Why?
|
| Eye Infections, Bacterial | 1 | 2025 | 129 | 0.200 |
Why?
|
| Virus Diseases | 1 | 2004 | 39 | 0.200 |
Why?
|
| Endophthalmitis | 1 | 2025 | 125 | 0.200 |
Why?
|
| Deafness | 2 | 1994 | 9 | 0.200 |
Why?
|
| Image Enhancement | 1 | 2004 | 59 | 0.200 |
Why?
|
| Retinal Degeneration | 1 | 2005 | 156 | 0.190 |
Why?
|
| Anemia, Aplastic | 1 | 2003 | 2 | 0.190 |
Why?
|
| Cohort Studies | 4 | 2016 | 903 | 0.190 |
Why?
|
| Young Adult | 2 | 2025 | 2877 | 0.190 |
Why?
|
| Severity of Illness Index | 4 | 2010 | 468 | 0.180 |
Why?
|
| Glucocorticoids | 6 | 2004 | 115 | 0.170 |
Why?
|
| Neuroma | 1 | 2001 | 5 | 0.170 |
Why?
|
| Cranial Nerve Neoplasms | 1 | 2001 | 7 | 0.170 |
Why?
|
| Reading | 1 | 2001 | 19 | 0.170 |
Why?
|
| Cranial Nerve Diseases | 2 | 2017 | 10 | 0.160 |
Why?
|
| Refraction, Ocular | 4 | 2008 | 26 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 6 | 2005 | 484 | 0.160 |
Why?
|
| Methylprednisolone | 3 | 2009 | 15 | 0.160 |
Why?
|
| Headache | 1 | 2020 | 37 | 0.160 |
Why?
|
| Intracranial Pressure | 2 | 2016 | 14 | 0.160 |
Why?
|
| Mycoplasma pneumoniae | 1 | 2020 | 11 | 0.160 |
Why?
|
| Neonatology | 1 | 2020 | 6 | 0.160 |
Why?
|
| Intravitreal Injections | 3 | 2020 | 34 | 0.160 |
Why?
|
| Puerperal Disorders | 1 | 2000 | 14 | 0.160 |
Why?
|
| Adrenocortical Carcinoma | 1 | 2000 | 5 | 0.160 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2000 | 4 | 0.160 |
Why?
|
| Adrenal Cortex Neoplasms | 1 | 2000 | 6 | 0.160 |
Why?
|
| Sphenoid Sinus | 1 | 2000 | 5 | 0.160 |
Why?
|
| Electroretinography | 4 | 2007 | 180 | 0.160 |
Why?
|
| Societies, Medical | 1 | 2020 | 93 | 0.160 |
Why?
|
| Postpartum Period | 1 | 2000 | 79 | 0.150 |
Why?
|
| Cataract Extraction | 2 | 1999 | 29 | 0.150 |
Why?
|
| Prescriptions | 1 | 2019 | 3 | 0.150 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2000 | 29 | 0.150 |
Why?
|
| Time Factors | 3 | 2016 | 1619 | 0.150 |
Why?
|
| Ocular Motility Disorders | 3 | 2000 | 3 | 0.150 |
Why?
|
| Intracranial Hypertension | 1 | 1999 | 8 | 0.150 |
Why?
|
| Brain | 3 | 2021 | 774 | 0.150 |
Why?
|
| Cerebral Veins | 1 | 1999 | 11 | 0.150 |
Why?
|
| Birth Weight | 5 | 2016 | 63 | 0.150 |
Why?
|
| Decision Support Techniques | 1 | 2019 | 51 | 0.150 |
Why?
|
| Cranial Fossa, Posterior | 1 | 2018 | 5 | 0.140 |
Why?
|
| Dura Mater | 1 | 2018 | 11 | 0.140 |
Why?
|
| Osteoporosis | 1 | 1999 | 63 | 0.140 |
Why?
|
| Guideline Adherence | 1 | 2019 | 97 | 0.140 |
Why?
|
| Retinal Pigment Epithelium | 1 | 2019 | 100 | 0.140 |
Why?
|
| Fundus Oculi | 4 | 2013 | 15 | 0.140 |
Why?
|
| Acetazolamide | 3 | 2009 | 9 | 0.130 |
Why?
|
| Cochlear Implants | 2 | 1994 | 14 | 0.130 |
Why?
|
| Edrophonium | 1 | 1997 | 1 | 0.130 |
Why?
|
| Parasympathomimetics | 1 | 1997 | 3 | 0.130 |
Why?
|
| Autoantibodies | 1 | 2020 | 488 | 0.130 |
Why?
|
| Vitreous Hemorrhage | 1 | 2016 | 1 | 0.130 |
Why?
|
| Retinal Hemorrhage | 1 | 2016 | 7 | 0.130 |
Why?
|
| Abnormalities, Multiple | 1 | 1997 | 35 | 0.130 |
Why?
|
| Lyme Disease | 1 | 1997 | 26 | 0.120 |
Why?
|
| Vision, Low | 1 | 2016 | 4 | 0.120 |
Why?
|
| Spinal Puncture | 1 | 2016 | 11 | 0.120 |
Why?
|
| Health Plan Implementation | 1 | 2016 | 9 | 0.120 |
Why?
|
| Gels | 2 | 2008 | 27 | 0.120 |
Why?
|
| Brain Neoplasms | 1 | 2000 | 315 | 0.120 |
Why?
|
| History, 21st Century | 1 | 2016 | 50 | 0.120 |
Why?
|
| Growth Hormone | 1 | 1997 | 103 | 0.120 |
Why?
|
| Eye Diseases | 1 | 1996 | 31 | 0.120 |
Why?
|
| Nervous System Diseases | 1 | 1996 | 40 | 0.120 |
Why?
|
| Shaken Baby Syndrome | 1 | 2016 | 5 | 0.120 |
Why?
|
| Color Perception Tests | 2 | 2011 | 2 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2016 | 76 | 0.120 |
Why?
|
| Craniocerebral Trauma | 1 | 2016 | 27 | 0.120 |
Why?
|
| Double-Blind Method | 2 | 2008 | 426 | 0.110 |
Why?
|
| Dopamine Agents | 1 | 2015 | 2 | 0.110 |
Why?
|
| Levodopa | 1 | 2015 | 11 | 0.110 |
Why?
|
| Oklahoma | 2 | 2025 | 1063 | 0.110 |
Why?
|
| Bandages | 1 | 2015 | 15 | 0.110 |
Why?
|
| Child Abuse | 1 | 2016 | 93 | 0.110 |
Why?
|
| Hearing Disorders | 1 | 1994 | 2 | 0.110 |
Why?
|
| Retinal Vein Occlusion | 1 | 2014 | 2 | 0.100 |
Why?
|
| Optic Neuropathy, Ischemic | 1 | 2014 | 3 | 0.100 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2001 | 998 | 0.100 |
Why?
|
| Sensory Thresholds | 3 | 2007 | 14 | 0.100 |
Why?
|
| Adaptation, Ocular | 1 | 2013 | 7 | 0.100 |
Why?
|
| Botulinum Toxins | 1 | 1993 | 10 | 0.100 |
Why?
|
| History, 19th Century | 1 | 2013 | 37 | 0.100 |
Why?
|
| Thalamus | 1 | 1993 | 27 | 0.100 |
Why?
|
| Cryosurgery | 2 | 2007 | 19 | 0.100 |
Why?
|
| Cerebral Infarction | 1 | 1993 | 26 | 0.100 |
Why?
|
| Proportional Hazards Models | 1 | 2014 | 226 | 0.100 |
Why?
|
| Prevalence | 7 | 2016 | 526 | 0.100 |
Why?
|
| Syndrome | 2 | 2011 | 79 | 0.100 |
Why?
|
| Antibodies, Bacterial | 1 | 1993 | 108 | 0.100 |
Why?
|
| Photography | 2 | 2011 | 19 | 0.100 |
Why?
|
| Vision, Ocular | 1 | 1993 | 27 | 0.090 |
Why?
|
| Hodgkin Disease | 1 | 1992 | 12 | 0.090 |
Why?
|
| Temporal Arteries | 1 | 2012 | 3 | 0.090 |
Why?
|
| Papilledema | 3 | 2003 | 8 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2020 | 614 | 0.090 |
Why?
|
| Meta-Analysis as Topic | 1 | 2012 | 33 | 0.090 |
Why?
|
| Retinal Vessels | 1 | 2013 | 75 | 0.090 |
Why?
|
| Torticollis | 2 | 2007 | 3 | 0.090 |
Why?
|
| Sensitivity and Specificity | 4 | 2016 | 526 | 0.090 |
Why?
|
| Odds Ratio | 1 | 2012 | 237 | 0.090 |
Why?
|
| Reoperation | 2 | 2003 | 159 | 0.090 |
Why?
|
| Clinical Protocols | 1 | 2012 | 46 | 0.090 |
Why?
|
| Injections, Intraperitoneal | 1 | 2011 | 35 | 0.090 |
Why?
|
| Retinal Neovascularization | 1 | 2011 | 21 | 0.090 |
Why?
|
| Retinal Vein | 1 | 2011 | 2 | 0.090 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2011 | 6 | 0.090 |
Why?
|
| Retinal Artery | 1 | 2011 | 10 | 0.090 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2011 | 21 | 0.090 |
Why?
|
| Arteriovenous Malformations | 1 | 2011 | 16 | 0.080 |
Why?
|
| Arteriovenous Fistula | 1 | 2011 | 16 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2011 | 741 | 0.080 |
Why?
|
| Animals, Newborn | 1 | 2011 | 183 | 0.080 |
Why?
|
| Organizational Policy | 1 | 2010 | 19 | 0.080 |
Why?
|
| Oximetry | 1 | 2010 | 11 | 0.080 |
Why?
|
| Suture Techniques | 2 | 2001 | 29 | 0.080 |
Why?
|
| Pandemics | 2 | 2022 | 211 | 0.080 |
Why?
|
| Eye Movements | 3 | 2001 | 12 | 0.080 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2009 | 26 | 0.080 |
Why?
|
| African Americans | 1 | 2012 | 353 | 0.080 |
Why?
|
| Cost-Benefit Analysis | 2 | 2006 | 116 | 0.070 |
Why?
|
| Refractive Errors | 2 | 1999 | 6 | 0.070 |
Why?
|
| Administration, Topical | 1 | 2008 | 31 | 0.070 |
Why?
|
| Vision Tests | 2 | 1999 | 3 | 0.070 |
Why?
|
| Christianity | 1 | 2008 | 3 | 0.070 |
Why?
|
| Religion and Medicine | 1 | 2008 | 6 | 0.070 |
Why?
|
| Cross-Sectional Studies | 1 | 2011 | 1013 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2020 | 108 | 0.070 |
Why?
|
| Data Collection | 1 | 2008 | 109 | 0.070 |
Why?
|
| Elective Surgical Procedures | 1 | 2008 | 74 | 0.060 |
Why?
|
| Cryotherapy | 3 | 2005 | 10 | 0.060 |
Why?
|
| Anti-Bacterial Agents | 2 | 2004 | 540 | 0.060 |
Why?
|
| San Francisco | 1 | 2026 | 12 | 0.060 |
Why?
|
| Disease Models, Animal | 1 | 2011 | 1524 | 0.060 |
Why?
|
| Cerebral Angiography | 2 | 2011 | 38 | 0.060 |
Why?
|
| Cost of Illness | 1 | 2006 | 54 | 0.060 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2005 | 15 | 0.060 |
Why?
|
| Safety | 1 | 2004 | 33 | 0.050 |
Why?
|
| Ophthalmic Solutions | 1 | 2004 | 27 | 0.050 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2004 | 28 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 1 | 2006 | 250 | 0.050 |
Why?
|
| Hernia | 1 | 2004 | 9 | 0.050 |
Why?
|
| Cerebral Arteries | 1 | 2004 | 34 | 0.050 |
Why?
|
| Fluorometholone | 1 | 2004 | 4 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2003 | 12 | 0.050 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2005 | 254 | 0.050 |
Why?
|
| Drug Therapy, Combination | 1 | 2004 | 210 | 0.050 |
Why?
|
| Antilymphocyte Serum | 1 | 2003 | 4 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2016 | 1288 | 0.050 |
Why?
|
| Surveys and Questionnaires | 1 | 2007 | 1021 | 0.050 |
Why?
|
| School Admission Criteria | 1 | 2022 | 6 | 0.050 |
Why?
|
| Blood Transfusion | 1 | 2003 | 77 | 0.050 |
Why?
|
| Ischemia | 2 | 1993 | 83 | 0.050 |
Why?
|
| Diabetic Retinopathy | 1 | 2003 | 112 | 0.040 |
Why?
|
| Mice | 1 | 2011 | 4870 | 0.040 |
Why?
|
| Neurofibromatosis 1 | 1 | 2001 | 6 | 0.040 |
Why?
|
| Astigmatism | 1 | 2001 | 11 | 0.040 |
Why?
|
| Ophthalmoscopy | 2 | 2016 | 6 | 0.040 |
Why?
|
| Tendon Transfer | 1 | 2000 | 2 | 0.040 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2020 | 8 | 0.040 |
Why?
|
| Reproducibility of Results | 3 | 1999 | 794 | 0.040 |
Why?
|
| Antibodies, Antinuclear | 1 | 2001 | 183 | 0.040 |
Why?
|
| Prednisone | 1 | 2000 | 54 | 0.040 |
Why?
|
| Cerebral Ventricles | 1 | 2000 | 17 | 0.040 |
Why?
|
| China | 1 | 2020 | 64 | 0.040 |
Why?
|
| DNA | 1 | 2001 | 378 | 0.040 |
Why?
|
| Jugular Veins | 1 | 1999 | 13 | 0.040 |
Why?
|
| Constriction, Pathologic | 1 | 1999 | 36 | 0.040 |
Why?
|
| Lens Implantation, Intraocular | 1 | 1999 | 20 | 0.040 |
Why?
|
| Iris Neoplasms | 1 | 1998 | 2 | 0.040 |
Why?
|
| Mass Screening | 1 | 2020 | 160 | 0.040 |
Why?
|
| Optic Disk | 1 | 1998 | 10 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 1999 | 485 | 0.040 |
Why?
|
| Nerve Compression Syndromes | 1 | 1998 | 13 | 0.040 |
Why?
|
| Glaucoma, Open-Angle | 1 | 1998 | 23 | 0.040 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 1998 | 44 | 0.030 |
Why?
|
| Intraocular Pressure | 1 | 1998 | 62 | 0.030 |
Why?
|
| Fovea Centralis | 1 | 1998 | 2 | 0.030 |
Why?
|
| Pregnancy, Multiple | 1 | 1998 | 8 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2000 | 244 | 0.030 |
Why?
|
| Albinism, Oculocutaneous | 1 | 1997 | 2 | 0.030 |
Why?
|
| Liver Transplantation | 1 | 1998 | 60 | 0.030 |
Why?
|
| Size Perception | 1 | 1997 | 4 | 0.030 |
Why?
|
| Reconstructive Surgical Procedures | 1 | 2018 | 72 | 0.030 |
Why?
|
| Animals | 1 | 2011 | 10806 | 0.030 |
Why?
|
| Septum Pellucidum | 1 | 1997 | 3 | 0.030 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 1997 | 3 | 0.030 |
Why?
|
| Myasthenia Gravis | 1 | 1997 | 3 | 0.030 |
Why?
|
| Hypopituitarism | 1 | 1997 | 5 | 0.030 |
Why?
|
| Corpus Callosum | 1 | 1997 | 20 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1997 | 102 | 0.030 |
Why?
|
| Color Perception | 1 | 1996 | 3 | 0.030 |
Why?
|
| Granuloma | 1 | 1996 | 18 | 0.030 |
Why?
|
| Color Vision Defects | 1 | 1996 | 12 | 0.030 |
Why?
|
| Geniculate Bodies | 1 | 1996 | 3 | 0.030 |
Why?
|
| Allied Health Personnel | 1 | 2016 | 14 | 0.030 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 1998 | 131 | 0.030 |
Why?
|
| Encephalitis | 1 | 1996 | 18 | 0.030 |
Why?
|
| Needlestick Injuries | 1 | 1996 | 3 | 0.030 |
Why?
|
| Acute Disease | 1 | 2016 | 158 | 0.030 |
Why?
|
| Bupivacaine | 1 | 1996 | 4 | 0.030 |
Why?
|
| Anesthesia, Local | 1 | 1996 | 5 | 0.030 |
Why?
|
| Sarcoidosis | 1 | 1996 | 38 | 0.030 |
Why?
|
| Contracture | 1 | 1996 | 4 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 1996 | 31 | 0.030 |
Why?
|
| Injections | 1 | 1996 | 31 | 0.030 |
Why?
|
| Lidocaine | 1 | 1996 | 27 | 0.030 |
Why?
|
| Eye Injuries | 1 | 1996 | 11 | 0.030 |
Why?
|
| Orbit | 1 | 1996 | 12 | 0.030 |
Why?
|
| Anesthetics, Local | 1 | 1996 | 12 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2017 | 179 | 0.030 |
Why?
|
| Cadaver | 1 | 1996 | 61 | 0.030 |
Why?
|
| Diarrhea | 1 | 1996 | 58 | 0.030 |
Why?
|
| Jurisprudence | 1 | 2016 | 5 | 0.030 |
Why?
|
| Liability, Legal | 1 | 2016 | 6 | 0.030 |
Why?
|
| Abducens Nerve | 1 | 1995 | 1 | 0.030 |
Why?
|
| Facial Paralysis | 1 | 1995 | 2 | 0.030 |
Why?
|
| Facial Nerve | 1 | 1995 | 7 | 0.030 |
Why?
|
| Diabetic Neuropathies | 1 | 1995 | 18 | 0.030 |
Why?
|
| Health Surveys | 1 | 2016 | 88 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2016 | 233 | 0.030 |
Why?
|
| Anisometropia | 1 | 2015 | 1 | 0.030 |
Why?
|
| Hypertrophy | 1 | 1994 | 46 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2015 | 191 | 0.030 |
Why?
|
| Eye Pain | 1 | 2014 | 1 | 0.030 |
Why?
|
| Blepharospasm | 1 | 1993 | 1 | 0.030 |
Why?
|
| Spasm | 1 | 1993 | 4 | 0.030 |
Why?
|
| Facial Muscles | 1 | 1993 | 8 | 0.030 |
Why?
|
| Immunoassay | 1 | 1993 | 36 | 0.030 |
Why?
|
| Gadolinium | 1 | 1993 | 6 | 0.030 |
Why?
|
| Hemianopsia | 1 | 1993 | 1 | 0.020 |
Why?
|
| Arteritis | 1 | 1993 | 3 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 1993 | 44 | 0.020 |
Why?
|
| Skull | 1 | 1993 | 41 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 1993 | 75 | 0.020 |
Why?
|
| Retinal Artery Occlusion | 1 | 1992 | 1 | 0.020 |
Why?
|
| Sex Distribution | 2 | 2005 | 78 | 0.020 |
Why?
|
| Receptors, Adrenergic, beta | 1 | 2012 | 24 | 0.020 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2012 | 66 | 0.020 |
Why?
|
| Polymorphism, Genetic | 1 | 2012 | 166 | 0.020 |
Why?
|
| Uveal Neoplasms | 1 | 1989 | 8 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1989 | 26 | 0.020 |
Why?
|
| Family Health | 1 | 1989 | 71 | 0.020 |
Why?
|
| Family | 1 | 1989 | 99 | 0.020 |
Why?
|
| Melanoma | 1 | 1989 | 140 | 0.020 |
Why?
|
| Scotoma | 1 | 2005 | 6 | 0.010 |
Why?
|
| Retinoscopy | 1 | 2005 | 1 | 0.010 |
Why?
|
| Laser Coagulation | 1 | 2005 | 13 | 0.010 |
Why?
|
| Age Distribution | 1 | 2005 | 75 | 0.010 |
Why?
|
| Genes, Recessive | 1 | 2003 | 21 | 0.010 |
Why?
|
| Genetic Markers | 1 | 2003 | 92 | 0.010 |
Why?
|
| Pedigree | 1 | 2003 | 156 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 2003 | 128 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2003 | 126 | 0.010 |
Why?
|
| Haplotypes | 1 | 2003 | 290 | 0.010 |
Why?
|
| Retinal Detachment | 1 | 2001 | 11 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2000 | 66 | 0.010 |
Why?
|
| Sclera | 1 | 2000 | 11 | 0.010 |
Why?
|
| Lens Capsule, Crystalline | 1 | 1999 | 1 | 0.010 |
Why?
|
| Observer Variation | 1 | 1999 | 46 | 0.010 |
Why?
|
| Biliary Atresia | 1 | 1998 | 4 | 0.010 |
Why?
|
| Lymphoproliferative Disorders | 1 | 1998 | 6 | 0.010 |
Why?
|
| Cataract | 1 | 1999 | 29 | 0.010 |
Why?
|
| Prognosis | 1 | 2000 | 817 | 0.010 |
Why?
|
| Convergence, Ocular | 1 | 1997 | 1 | 0.010 |
Why?
|
| Vision Disparity | 1 | 1997 | 1 | 0.010 |
Why?
|
| Florida | 1 | 1998 | 55 | 0.010 |
Why?
|
| Medical Records | 1 | 1997 | 52 | 0.010 |
Why?
|
| Panuveitis | 1 | 1996 | 1 | 0.010 |
Why?
|
| Pregnancy Outcome | 1 | 1998 | 131 | 0.010 |
Why?
|
| Methylprednisolone Hemisuccinate | 1 | 1996 | 2 | 0.010 |
Why?
|
| Prednisolone | 1 | 1996 | 6 | 0.010 |
Why?
|
| Necrosis | 1 | 1996 | 85 | 0.010 |
Why?
|
| Travel | 1 | 1996 | 12 | 0.010 |
Why?
|
| Fever | 1 | 1996 | 31 | 0.010 |
Why?
|
| Anti-Inflammatory Agents | 1 | 1996 | 128 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 1995 | 125 | 0.010 |
Why?
|
| Pregnancy | 1 | 1998 | 1261 | 0.010 |
Why?
|
| Myelin Sheath | 1 | 1993 | 28 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 1995 | 346 | 0.010 |
Why?
|
| Obesity | 1 | 1997 | 705 | 0.010 |
Why?
|
| Connecticut | 1 | 1989 | 4 | 0.000 |
Why?
|
| Peritoneal Neoplasms | 1 | 1989 | 80 | 0.000 |
Why?
|
| Skin Neoplasms | 1 | 1989 | 147 | 0.000 |
Why?
|